In this touchINFECTIOUS DISEASES interview, we met with Dr Martin Hoenigl (Medical University of Graz, Austria) to discuss ECMM Candida III Multinational European study, which collected data on epidemiology, risk factors, treatment, and outcomes of culture proven candidemia across Europe, to assess how adherence to guideline recommendations correlate with outcomes.
The abstract entitled: ‘Guideline Adherence Predicts Outcomes of Candidemia in Europe: Results from the ECMM Candida III Multinational European study’ was presented at IDWeek 2022, 19-23 October 2022.
Interviews available in this series:
Candidemia prognosis and unmet needs in its treatment
Guideline adherence predicts outcomes of candidemia in Europe
Questions:
- What were the objectives and methodology of your study? (0:12)
- How did guideline adherence impact mortality and hospitalisation? (1:43)
- What were the conclusions of the investigators? (3:40)
Disclosures: Martin Hoenigl is a consultant for Scynexis, Pulmocide, Gilead, Euro Pharma Holings, and Mundipharma; receives grant/research support from Gilead, Scynexis, Pfizer, MSD, Euroimun, and Mundipharma; and is on the advisory board for F2G.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
